Pulmonology

The ALK-Abello expert details the positive findings from the vast, novel assessment of Ragwitek in children with ragweed allergic rhinitis with or without conjunctivitis.

New findings show Viaskin Peanut provided significant improvements to HRQL over placebo in a pair of its clinical trials.

Distinguishing biologic-eligible patients may still need further biomarker and disease severity research.

The rate of ED cases have decreased over years, yet proper patient follow-up is still lacking.

Clinicians now have 5 agents to select from—but a limited variation of action, and an even more concise patient population eligible for treatment.

How the annual college meeting has come to address the rapidly developing field of immunotherapy.

With new immunotherapy data and emerging biologic uses, allergists need to adjust their standards for diagnosis and care in pediatric patients.

A new survey shows patients and family members prefer telemedicine physician visits as much as they do in-person appointments—or even more so than the latter.

A 20-patient survey evidences the benefit of subcutaneous immunotherapy among patients aged 9-18 years old.

New findings from the phase 3 PALISADE and ARTEMIS trials show more than half of treated patients could tolerate 1000 mg peanut protein in a post-care food challenge.

After decades of development, researchers are nearing clinical trials for immune response-shifting vaccines. Will they be feasible for patients, and accepted by clinicians?

A new study from Icahn School of Medicine at Mount Sinai found increases in exposure to fine particulate matter before birth were associated with heart rate variability during infancy.

A new assessment shows patients younger and older than 40 years both benefit in exacerbation rate and pre-bronchodilator FEV1.

A new study presented at CHEST 2019 shows pulmonologists and ILD specialists will either reduce or temporarily interrupt antifibrotic care, depending on the form of adverse events a patient is experiencing.

A new study shows that bronchoscopy practice, procedure, and tools vary by facility, and in assessment duration.

A study comparing the LAMA/LABA to monotherapy found patients without prior ICS treatment benefitted significantly, regardless of disease severity or symptoms.

A comparative cohort found inpatient and outpatient costs, both for respiratory and all-cause conditions, were less per month for patients on the antifibrotic.

New findings from the phase 3 trial show budesonide/ glycopyrrolate/ formoterol fumarate significantly reduces exacerbations among patients with no exacerbation history, compared to dual therapies.

A Cleveland Clinic study showed about 13% of its transfusions were in deference to current guidelines. That said, there's plenty of gray area for cause of care.

From medical marijuana to vape devices, there seems to be a divide in defining what's legal for use, and what's actually beneficial for users.

How the LAMA therapy manages one of the integral facets of COPD care.

While one disease is benefitting from advancing digital screening measures, the other has a standard therapy which could provide benefit to both.

A new study finds the months of January-March are most burdened with COPD exacerbation-based hospitalizations, mortality, and hospital costs.

How should physicians navigate the public belief that vaping is less harmful than cigarette smoking?

A new study shows the underutilized test could reveal an additional 9% of asthma diagnoses and potentially 8% of asthma-COPD overlap syndrome cases.